ULTACAN FORTE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ultacan Forte, and when can generic versions of Ultacan Forte launch?
Ultacan Forte is a drug marketed by Hansamed Inc and is included in one NDA.
The generic ingredient in ULTACAN FORTE is articaine hydrochloride; epinephrine bitartrate. There are seven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the articaine hydrochloride; epinephrine bitartrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ULTACAN FORTE?
- What are the global sales for ULTACAN FORTE?
- What is Average Wholesale Price for ULTACAN FORTE?
Summary for ULTACAN FORTE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | ULTACAN FORTE at DailyMed |
US Patents and Regulatory Information for ULTACAN FORTE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hansamed Inc | ULTACAN FORTE | articaine hydrochloride; epinephrine bitartrate | INJECTABLE;INJECTION | 201750-001 | Jul 11, 2017 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
